Sanofi-Aventis to reinforce its presence in Russia via the 'Pharmpolis Project;' Multaq approved by EC

30 November 2009

Drug major Sanofi-Aventis was in the news on two fronts: it has received final approval to market its arrhythmia drug Multaq (dronedarone) in the European Union and has signed a memorandum of understanding with Prominvest, a wholly-owned subsidiary of the Russian state corporation Rostekhnologii, confirming its intent to participate in the 'Pharmpolis Project' using the French company's new modern insulin factory located in Russia as a pilot initiative.

Sanofi-Aventis last month announced plans to buy a 74% stake in Bioton-Vostok, a Russian manufacturer of insulins.

The document was signed by Mikhail Shelkov, general director of LLC Prominvest and Christopher Viehbacher, chief executive of Sanofi-Aventis, during the Franco-Russian Intergovernmental Seminar held in the Castle of Rambouillet, France, in the presence of Vladimir Putin, Prime Minister of the Russian Federation, and François Fillon, Prime Minister of France.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK